Mechanisms of resistance to anti-EGFR therapy in colorectal cancer

Oncotarget

Volumn 8, Issue 3, 2017, Pages 3980-4000

  Zhao, Ben ^a   Wang, Lu ^a   Qiu, Hong ^a   Zhang, Mingsheng ^a   Sun, Li ^a   Peng, Ping ^a   Yu, Qianqian ^a   Yuan, Xianglin ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Acquired resistance; Colorectal cancer; Epidermal growth factor receptor; Primary resistance; Targeted drug

Indexed keywords

B RAF KINASE; CETUXIMAB; DALOTUZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; ERLOTINIB; GEFITINIB; GROWTH FACTOR RECEPTOR; IRINOTECAN; JANUS KINASE; K RAS PROTEIN; NEU DIFFERENTIATION FACTOR; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RAF PROTEIN; RAS PROTEIN; SCATTER FACTOR RECEPTOR; SOMATOMEDIN C RECEPTOR; SORAFENIB; STAT PROTEIN; TRASTUZUMAB; VASCULOTROPIN; EGFR PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PROTEIN KINASE INHIBITOR;

AREG GENE; ARTICLE; BRAF GENE; CANCER RESISTANCE; COLORECTAL CANCER; EGFR GENE; EPITHELIAL MESENCHYMAL TRANSITION; EXON; GENE ACTIVATION; GENE AMPLIFICATION; GENE DOSAGE; GENE LOSS; GENE MUTATION; GENE OVEREXPRESSION; HER3 GENE; HER4 GENE; HUMAN; IGF 1R GENE; JAK GENE; MET GENE; NRAS GENE; ONCOGENE K RAS; ONCOGENE NEU; ONCOGENE RAS; PIK3CA GENE; PTEN GENE; RAF GENE; SIGNAL TRANSDUCTION; STAT GENE; VEGF GENE; COLORECTAL TUMOR; DRUG EFFECT; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETICS; METASTASIS; MUTATION;

ANTIBODIES, MONOCLONAL; CETUXIMAB; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; ERBB RECEPTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; HUMANS; MUTATION; NEOPLASM METASTASIS; PANITUMUMAB; PROTEIN KINASE INHIBITORS; RAS PROTEINS; SIGNAL TRANSDUCTION;

EID: 85012004445     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.14012     Document Type: Article

References (123)

1. Siegel R, Desantis C, and Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin. 2014; 64: 104-17. doi: 10.3322/caac.21220.
2. Misale S, Di Nicolantonio F, Sartore-Bianchi A, Siena S, and Bardelli A. Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. Cancer Discov. 2014; 4: 1269-80. doi: 10.1158/2159-8290.CD-14-0462.
3. Bokemeyer C, Bondarenko I, Hartmann JT, de Braud F, Schuch G, Zubel A, Celik I, Schlichting M, and Koralewski P. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol. 2011; 22: 1535-46. doi: 10.1093/annonc/mdq632.
4. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, Wolf M, and Amado RG. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapyrefractory metastatic colorectal cancer. J Clin Oncol. 2007; 25: 1658-64. doi: 10.1200/JCO.2006.08.1620.
5. Van Cutsem E, Kohne CH, Lang I, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S, Schlichting M, Zubel A, Celik I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011; 29: 2011-9. doi: 10.1200/JCO.2010.33.5091.
6. Tveit KM, Guren T, Glimelius B, Pfeiffer P, Sorbye H, Pyrhonen S, Sigurdsson F, Kure E, Ikdahl T, Skovlund E, Fokstuen T, Hansen F, Hofsli E, et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol. 2012; 30: 1755-62. doi: 10.1200/JCO.2011.38.0915.
7. Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, Idziaszczyk S, Harris R, Fisher D, Kenny SL, Kay E, Mitchell JK, Madi A, et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet. 2011; 377: 2103-14. doi: 10.1016/S0140-6736(11)60613-2.
8. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pinter T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009; 360: 1408-17. doi: 10.1056/NEJMoa0805019.
9. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocakova I, Ruff P, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010; 28: 4697-705. doi: 10.1200/JCO.2009.27.4860.
10. Meyerhardt JA, and Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med. 2005; 352: 476-87. doi: 10.1056/NEJMra040958.
11. Schwartzberg LS, Rivera F, Karthaus M, Fasola G, Canon JL, Hecht JR, Yu H, Oliner KS, and Go WY. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol. 2014; 32: 2240-7. doi: 10.1200/JCO.2013.53.2473.
12. Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmuller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014; 15: 1065-75. doi: 10.1016/S1470-2045(14)70330-4.
13. Lenz H, Niedzwiecki D, Innocenti F, Blanke C, Mahony MR, O'Neil BH, Shaw JE, Polite B, Hochster H, Atkins J, Goldberg R, Mayer R, Schilsky RL, et al. CALGB/SWOG 80405: phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or of oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (mCRC):expanded RAS analyses. Ann Oncol. 2014; 25: abstract 5010.
14. Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther. 1999; 82: 241-50. doi: 10.1016/S0163-7258(98)00045-X.
15. Yarden Y, and Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001; 2: 127-37 doi: 10.1038/35052073.
16. Ciardiello F, and Tortora G. EGFR antagonists in cancer treatment. N Engl J Med. 2008; 358: 1160-74. doi: 10.1056/NEJMra0707704.
17. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, Penault-Llorca F, Rougier P, Vincenzi B, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010; 11: 753-62. doi: 10.1016/S1470-2045(10)70130-3.
18. Hsu HC, Thiam TK, Lu YJ, Yeh CY, Tsai WS, You JF, Hung HY, Tsai CN, Hsu A, Chen HC, Chen SJ, and Yang TS. Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients. Oncotarget. 2016; 7: 22257-70. doi: 10.18632/oncotarget.8076.
19. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, and Van Cutsem E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004; 351: 337-45 doi: 10.1056/NEJMoa033025.
20. Bardelli A, and Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol. 2010; 28: 1254-61. doi: 10.1200/JCO.2009.24.6116.
21. Roock WD, Vriendt VD, Normanno N, Ciardiello F, and Tejpar S. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. The Lancet Oncology. 2011; 12: 594-603. doi: 10.1016/s1470-2045(10)70209-6.
22. Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, Gambacorta M, Siena S, and Bardelli A. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. The Lancet Oncology. 2005; 6: 279-86. doi: 10.1016/s1470-2045(05)70102-9.
23. Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, Wong TW, Huang X, Takimoto CH, Godwin AK, Tan BR, Krishnamurthi SS, Burris HA, 3rd, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol. 2007; 25: 3230-7. doi: 10.1200/JCO.2006.10.5437.
24. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350: 2129-39. doi: 10.1056/NEJMoa040938.
25. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, and Press M. Efficacy and safety of trastuzumab as a single agent in firstline treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002; 20: 719-26. doi: 10.1200/jco.2002.20.3.719.
26. Barber TD, Vogelstein B, Kinzler KW, and Velculescu VE. Somatic mutations of EGFR in colorectal cancers and glioblastomas. N Engl J Med. 2004; 351: 2883. doi: 10.1056/NEJM200412303512724.
27. Sartore-Bianchi A, Moroni M, Veronese S, Carnaghi C, Bajetta E, Luppi G, Sobrero A, Barone C, Cascinu S, Colucci G, Cortesi E, Nichelatti M, Gambacorta M, et al. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol. 2007; 25: 3238-45. doi: 10.1200/JCO.2007.11.5956.
28. Yang ZY, Shen WX, Hu XF, Zheng DY, Wu XY, Huang YF, Chen JZ, Mao C, and Tang JL. EGFR gene copy number as a predictive biomarker for the treatment of metastatic colorectal cancer with anti-EGFR monoclonal antibodies: a meta-analysis. J Hematol Oncol. 2012; 5: 52. doi: 10.1186/1756-8722-5-52.
29. Personeni N, Fieuws S, Piessevaux H, De Hertogh G, De Schutter J, Biesmans B, De Roock W, Capoen A, Debiec-Rychter M, Van Laethem JL, Peeters M, Humblet Y, Van Cutsem E, et al. Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study. Clin Cancer Res. 2008; 14: 5869-76. doi: 10.1158/1078-0432.CCR-08-0449.
30. Sartore-Bianchi A, Fieuws S, Veronese S, Moroni M, Personeni N, Frattini M, Torri V, Cappuzzo F, Vander Borght S, Martin V, Skokan M, Santoro A, Gambacorta M, et al. Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study. J Clin Pathol. 2012; 65: 218-23. doi: 10.1136/jclinpath-2011-200353.
31. Jacobs B, De Roock W, Piessevaux H, Van Oirbeek R, Biesmans B, De Schutter J, Fieuws S, Vandesompele J, Peeters M, Van Laethem JL, Humblet Y, Penault-Llorca F, De Hertogh G, et al. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol. 2009; 27: 5068-74. doi: 10.1200/JCO.2008.21.3744.
32. Malumbres M, and Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer. 2003; 3: 459-65. doi: 10.1038/nrc1097.
33. Bos JL. ras oncogenes in human cancer: a review. Cancer Res. 1989; 49: 4682-9.
34. Fernandez-Medarde A, and Santos E. Ras in cancer and developmental diseases. Genes Cancer. 2011; 2: 344-58. doi: 10.1177/1947601911411084.
35. Allegra CJ, Rumble RB, Hamilton SR, Mangu PB, Roach N, Hantel A, and Schilsky RL. Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015. J Clin Oncol. 2016; 34: 179-85. doi: 10.1200/JCO.2015.63.9674.
36. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, and Chang DD. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008; 26: 1626-34. doi: 10.1200/JCO.2007.14.7116.
37. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, McAllister PK, Morton RF, and Schilsky RL. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 2009; 27: 2091-6 doi: 10.1200/JCO.2009.21.9170.
38. De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, Lamba S, Arena S, Frattini M, Piessevaux H, Van Cutsem E, O'Callaghan CJ, Khambata-Ford S, et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA. 2010; 304: 1812-20. doi: 10.1001/jama.2010.1535.
39. Tejpar S, Celik I, Schlichting M, Sartorius U, Bokemeyer C, and Van Cutsem E. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol. 2012; 30: 3570-7. doi: 10.1200/JCO.2012.42.2592.
40. Gajate P, Sastre J, Bando I, Alonso T, Cillero L, Sanz J, Caldes T, and Diaz-Rubio E. Influence of KRAS p.G13D mutation in patients with metastatic colorectal cancer treated with cetuximab. Clin Colorectal Cancer. 2012; 11: 291-6. doi: 10.1016/j.clcc.2012.02.003.
41. Peeters M, Douillard JY, Van Cutsem E, Siena S, Zhang K, Williams R, and Wiezorek J. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab. J Clin Oncol. 2013; 31: 759-65. doi: 10.1200/JCO.2012.45.1492.
42. Bokemeyer C, Kohne CH, Ciardiello F, Lenz HJ, Heinemann V, Klinkhardt U, Beier F, Duecker K, and Tejpar S. Treatment outcome according to tumor RAS mutation status in OPUS study patients with metastatic colorectal cancer (mCRC) randomized to FOLFOX4 with/without cetuximab. J Clin Oncol. 2014; 32(5s): abstract 3505.
43. Ciardiello F, Lenz HJ, Kohne CH, Heinemann V, Tejpar S, Melezinek I, Beier F, Stroh C, and EV. C. Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without cetuximab. J Clin Oncol. 2014; 32: abstract 3506.
44. Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocakova I, Ruff P, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013; 369: 1023-34. doi: 10.1056/NEJMoa1305275.
45. Stintzing S, Jung A, Rossius L, Modest DP, Fischer von Weikersthal L, Decker T, Kiani A, Möhler M, Kirchner T, and Heinemann V. Analysis of KRAS/NRAS and BRAF mutations in FIRE-3: a randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients. Eur J Cancer. 2014; 49: abstract LBA-17.
46. Van Cutsem E, Lenz HJ, Kohne CH, Heinemann V, Tejpar S, Melezinek I, Beier F, Stroh C, Rougier P, van Krieken JH, and Ciardiello F. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol. 2015; 33: 692-700. doi: 10.1200/JCO.2014.59.4812.
47. Tol J, Nagtegaal ID, and Punt CJ. BRAF mutation in metastatic colorectal cancer. N Engl J Med. 2009; 361: 98-9 doi: 10.1056/NEJMc0904160.
48. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, et al. Mutations of the BRAF gene in human cancer. Nature. 2002; 417: 949-54. doi: 10.1038/nature00766.
49. Ikenoue T, Hikiba Y, Kanai F, Tanaka Y, Imamura J, Imamura T, Ohta M, Ijichi H, Tateishi K, Kawakami T, Aragaki J, Matsumura M, Kawabe T, et al. Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors. Cancer Res. 2003; 63: 8132-7.
50. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D, Marais R, and Cancer Genome P. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004; 116: 855-67. doi: 10.1016/S0092-8674(04)00215-6.
51. Seymour MT, Brown SR, Middleton G, Maughan T, Richman S, Gwyther S, Lowe C, Seligmann JF, Wadsley J, Maisey N, Chau I, Hill M, Dawson L, et al. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Lancet Oncol. 2013; 14: 749-59. doi: 10.1016/S1470-2045(13)70163-3.
52. Rowland A, Dias MM, Wiese MD, Kichenadasse G, McKinnon RA, Karapetis CS, and Sorich MJ. Metaanalysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. Br J Cancer. 2015; 112: 1888-94. doi: 10.1038/bjc.2015.173.
53. Capalbo C, Marchetti P, Coppa A, Calogero A, Anastasi E, Buffone A, Belardinilli F, Gulino M, Frati P, Catalano C, Cortesi E, Giannini G, and Gulino A. Vemurafenib and panitumumab combination tailored therapy in BRAFmutated metastatic colorectal cancer: a case report. Cancer Biol Ther. 2014; 15: 826-31. doi: 10.4161/cbt.28878.
54. Al-Marrawi MY, Saroya BS, Brennan MC, Yang Z, Dykes TM, and El-Deiry WS. Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer. Cancer Biol Ther. 2013; 14: 703-10. doi: 10.4161/cbt.25191.
55. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, and Velculescu VE. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature. 2002; 418: 934. doi: 10.1038/418934a.
56. Nosho K, Kawasaki T, Ohnishi M, Suemoto Y, Kirkner GJ, Zepf D, Yan L, Longtine JA, Fuchs CS, and Ogino S. PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. Neoplasia. 2008; 10: 534-41. doi: 10.1593/neo.08336.
57. Barault L, Veyrie N, Jooste V, Lecorre D, Chapusot C, Ferraz JM, Lievre A, Cortet M, Bouvier AM, Rat P, Roignot P, Faivre J, Laurent-Puig P, et al. Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. Int J Cancer. 2008; 122: 2255-9. doi: 10.1002/ijc.23388.
58. Perrone F, Lampis A, Orsenigo M, Di Bartolomeo M, Gevorgyan A, Losa M, Frattini M, Riva C, Andreola S, Bajetta E, Bertario L, Leo E, Pierotti MA, et al. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol. 2009; 20: 84-90. doi: 10.1093/annonc/mdn541.
59. Sartore-Bianchi A, Martini M, Molinari F, Veronese S, Nichelatti M, Artale S, Di Nicolantonio F, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, and Bardelli A. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res. 2009; 69: 1851-7. doi: 10.1158/0008-5472.CAN-08-2466.
60. Prenen H, De Schutter J, Jacobs B, De Roock W, Biesmans B, Claes B, Lambrechts D, Van Cutsem E, and Tejpar S. PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin Cancer Res. 2009; 15: 3184-8. doi: 10.1158/1078-0432.CCR-08-2961.
61. Zhao L, and Vogt PK. Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci U S A. 2008; 105: 2652-7. doi: 10.1073/pnas.0712169105.
62. Mao C, Yang ZY, Hu XF, Chen Q, and Tang JL. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and metaanalysis. Ann Oncol. 2012; 23: 1518-25. doi: 10.1093/annonc/mdr464.
63. Goel A, Arnold CN, Niedzwiecki D, Carethers JM, Dowell JM, Wasserman L, Compton C, Mayer RJ, Bertagnolli MM, and Boland CR. Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. Cancer Res. 2004; 64: 3014-21. doi: 10.1158/0008-5472.CAN-2401-2.
64. Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, and Bardelli A. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst. 2009; 101: 1308-24. doi: 10.1093/jnci/djp280.
65. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung MC, and Yu D. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell. 2004; 6: 117-27. doi: 10.1016/j.ccr.2004.06.022.
66. Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, Rougier P, Lievre A, Landi B, Boige V, Ducreux M, Ychou M, Bibeau F, et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol. 2009; 27: 5924-30. doi: 10.1200/JCO.2008.21.6796.
67. Loupakis F, Pollina L, Stasi I, Ruzzo A, Scartozzi M, Santini D, Masi G, Graziano F, Cremolini C, Rulli E, Canestrari E, Funel N, Schiavon G, et al. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol. 2009; 27: 2622-9. doi: 10.1200/JCO.2008.20.2796.
68. Ma XT, Wang S, Ye YJ, Du RY, Cui ZR, and Somsouk M. Constitutive activation of Stat3 signaling pathway in human colorectal carcinoma. World J Gastroenterol. 2004; 10: 1569-73.
69. Kisseleva T, Bhattacharya S, Braunstein J, and Schindler CW. Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene. 2002; 285: 1-24. doi: 10.1016/S0378-1119(02)00398-0.
70. Kijima T, Niwa H, Steinman RA, Drenning SD, Gooding WE, Wentzel AL, Xi S, and Grandis JR. STAT3 activation abrogates growth factor dependence and contributes to head and neck squamous cell carcinoma tumor growth in vivo. Cell Growth Differ. 2002; 13: 355-62.
71. Haura EB, Sommers E, Song L, Chiappori A, and Becker A. A pilot study of preoperative gefitinib for early-stage lung cancer to assess intratumor drug concentration and pathways mediating primary resistance. J Thorac Oncol. 2010; 5: 1806-14. doi: 10.1097/JTO.0b013e3181f38f70.
72. Li Q, Zhang D, Chen X, He L, Li T, Xu X, and Li M. Nuclear PKM2 contributes to gefitinib resistance via upregulation of STAT3 activation in colorectal cancer. Sci Rep. 2015; 5: 16082. doi: 10.1038/srep16082.
73. Yar Saglam AS, Alp E, Elmazoglu Z, and Menevse S. Treatment with cucurbitacin B alone and in combination with gefitinib induces cell cycle inhibition and apoptosis via EGFR and JAK/STAT pathway in human colorectal cancer cell lines. Hum Exp Toxicol. 2016; 35: 526-43. doi: 10.1177/0960327115595686.
74. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002; 2: 442-54. doi: 10.1038/nrc822.
75. Tan TZ, Miow QH, Miki Y, Noda T, Mori S, Huang RY, and Thiery JP. Epithelial-mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients. EMBO Mol Med. 2014; 6: 1279-93. doi: 10.15252/emmm.201404208.
76. Thomson S, Petti F, Sujka-Kwok I, Epstein D, and Haley JD. Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy. Clin Exp Metastasis. 2008; 25: 843-54. doi: 10.1007/s10585-008-9200-4.
77. Buck E, Eyzaguirre A, Barr S, Thompson S, Sennello R, Young D, Iwata KK, Gibson NW, Cagnoni P, and Haley JD. Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition. Mol Cancer Ther. 2007; 6: 532-41 doi: 10.1158/1535-7163.MCT-06-0462.
78. De Luca A, Arra C, D'Antonio A, Casamassimi A, Losito S, Ferraro P, Ciardiello F, Salomon DS, and Normanno N. Simultaneous blockage of different EGF-like growth factors results in efficient growth inhibition of human colon carcinoma xenografts. Oncogene. 2000; 19: 5863-71.
79. Schmitz S, Bindea G, Albu RI, Mlecnik B, and Machiels JP. Cetuximab promotes epithelial to mesenchymal transition and cancer associated fibroblasts in patients with head and neck cancer. Oncotarget. 2015; 6: 34288-99. doi: 10.18632/oncotarget.5924.
80. Yauch RL, Januario T, Eberhard DA, Cavet G, Zhu W, Fu L, Pham TQ, Soriano R, Stinson J, Seshagiri S, Modrusan Z, Lin CY, O'Neill V, et al. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res. 2005; 11: 8686-98. doi: 10.1158/1078-0432. CCR-05-1492.
81. Van Emburgh BO, Sartore-Bianchi A, Di Nicolantonio F, Siena S, and Bardelli A. Acquired resistance to EGFRtargeted therapies in colorectal cancer. Mol Oncol. 2014; 8: 1084-94. doi: 10.1016/j.molonc.2014.05.003.
82. Diaz LA, Jr., Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, Allen B, Bozic I, Reiter JG, Nowak MA, Kinzler KW, Oliner KS, and Vogelstein B. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012; 486: 537-40. doi: 10.1038/nature11219.
83. Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M, Siravegna G, Bencardino K, Cercek A, Chen CT, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012; 486: 532-6. doi: 10.1038/nature11156.
84. Bouchahda M, Karaboue A, Saffroy R, Innominato P, Gorden L, Guettier C, Adam R, and Levi F. Acquired KRAS mutations during progression of colorectal cancer metastases: possible implications for therapy and prognosis. Cancer Chemother Pharmacol. 2010; 66: 605-9. doi: 10.1007/s00280-010-1298-9.
85. Misale S, Arena S, Lamba S, Siravegna G, Lallo A, Hobor S, Russo M, Buscarino M, Lazzari L, Sartore-Bianchi A, Bencardino K, Amatu A, Lauricella C, et al. Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. Sci Transl Med. 2014; 6: 224ra26. doi: 10.1126/scitranslmed.3007947.
86. Weber MM, Fottner C, Liu SB, Jung MC, Engelhardt D, and Baretton GB. Overexpression of the insulin-like growth factor I receptor in human colon carcinomas. Cancer. 2002; 95: 2086-95. doi: 10.1002/cncr.10945.
87. Bardelli A, Corso S, Bertotti A, Hobor S, Valtorta E, Siravegna G, Sartore-Bianchi A, Scala E, Cassingena A, Zecchin D, Apicella M, Migliardi G, Galimi F, et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov. 2013; 3: 658-73. doi: 10.1158/2159-8290.CD-12-0558.
88. Wheeler DL, Huang S, Kruser TJ, Nechrebecki MM, Armstrong EA, Benavente S, Gondi V, Hsu KT, and Harari PM. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene. 2008; 27: 3944-56. doi: 10.1038/onc.2008.19.
89. Yu H, and Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst. 2000; 92: 1472-89. doi: 10.1093/jnci/92.18.1472.
90. Hu YP, Patil SB, Panasiewicz M, Li W, Hauser J, Humphrey LE, and Brattain MG. Heterogeneity of receptor function in colon carcinoma cells determined by crosstalk between type I insulin-like growth factor receptor and epidermal growth factor receptor. Cancer Res. 2008; 68: 8004-13. doi: 10.1158/0008-5472.CAN-08-0280.
91. Jones HE, Gee JM, Hutcheson IR, Knowlden JM, Barrow D, and Nicholson RI. Growth factor receptor interplay and resistance in cancer. Endocr Relat Cancer. 2006; 13 Suppl 1: S45-51. doi: 10.1677/erc.1.01275.
92. Scartozzi M, Mandolesi A, Giampieri R, Pierantoni C, Loupakis F, Zaniboni A, Galizia E, Giustini L, Silva RR, Bisonni R, Berardi R, Biagetti S, Menzo S, et al. Insulinlike growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan. Int J Cancer. 2010; 127: 1941-7. doi: 10.1002/ijc.25193.
93. Jones HE, Goddard L, Gee JM, Hiscox S, Rubini M, Barrow D, Knowlden JM, Williams S, Wakeling AE, and Nicholson RI. Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr Relat Cancer. 2004; 11: 793-814. doi: 10.1677/erc.1.00799.
94. Scartozzi M, Giampieri R, Maccaroni E, Mandolesi A, Giustini L, Silva R, Zaniboni A, Biscotti T, Biagetti S, Galizia E, Loupakis F, Falcone A, Bearzi I, et al. Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab. Ann Oncol. 2012; 23: 1706-12. doi: 10.1093/annonc/mdr558.
95. Ji QS, Mulvihill MJ, Rosenfeld-Franklin M, Cooke A, Feng L, Mak G, O'Connor M, Yao Y, Pirritt C, Buck E, Eyzaguirre A, Arnold LD, Gibson NW, et al. A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo. Mol Cancer Ther. 2007; 6: 2158-67. doi: 10.1158/1535-7163.MCT-07-0070.
96. Reidy DL, Vakiani E, Fakih MG, Saif MW, Hecht JR, Goodman-Davis N, Hollywood E, Shia J, Schwartz J, Chandrawansa K, Dontabhaktuni A, Youssoufian H, Solit DB, et al. Randomized, phase II study of the insulinlike growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab-or panitumumab-refractory metastatic colorectal cancer. J Clin Oncol. 2010; 28: 4240-6. doi: 10.1200/JCO.2010.30.4154.
97. Sclafani F, Kim TY, Cunningham D, Kim TW, Tabernero J, Schmoll HJ, Roh JK, Kim SY, Park YS, Guren TK, Hawkes E, Clarke SJ, Ferry D, et al. A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer. J Natl Cancer Inst. 2015; 107: djv258. doi: 10.1093/jnci/djv258.
98. Gherardi E, Birchmeier W, Birchmeier C, and Vande Woude G. Targeting MET in cancer: rationale and progress. Nat Rev Cancer. 2012; 12: 89-103. doi: 10.1038/nrc3205.
99. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007; 316: 1039-43. doi: 10.1126/science.1141478.
100. Yano S, Wang W, Li Q, Matsumoto K, Sakurama H, Nakamura T, Ogino H, Kakiuchi S, Hanibuchi M, Nishioka Y, Uehara H, Mitsudomi T, Yatabe Y, et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptoractivating mutations. Cancer Res. 2008; 68: 9479-87. doi: 10.1158/0008-5472.CAN-08-1643.
101. Troiani T, Martinelli E, Napolitano S, Vitagliano D, Ciuffreda LP, Costantino S, Morgillo F, Capasso A, Sforza V, Nappi A, De Palma R, D'Aiuto E, Berrino L, et al. Increased TGF-alpha as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells. Clin Cancer Res. 2013; 19: 6751-65. doi: 10.1158/1078-0432.CCR-13-0423.
102. Liska D, Chen CT, Bachleitner-Hofmann T, Christensen JG, and Weiser MR. HGF rescues colorectal cancer cells from EGFR inhibition via MET activation. Clin Cancer Res. 2011; 17: 472-82. doi: 10.1158/1078-0432.CCR-10-0568.
103. Krumbach R, Schuler J, Hofmann M, Giesemann T, Fiebig HH, and Beckers T. Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: activation of MET as one mechanism for drug resistance. Eur J Cancer. 2011; 47: 1231-43. doi: 10.1016/j. ejca.2010.12.019.
104. Yonesaka K, Zejnullahu K, Okamoto I, Satoh T, Cappuzzo F, Souglakos J, Ercan D, Rogers A, Roncalli M, Takeda M, Fujisaka Y, Philips J, Shimizu T, et al. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med. 2011; 3: 99ra86. doi: 10.1126/scitranslmed.3002442.
105. Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, Isella C, Cora D, Di Nicolantonio F, Buscarino M, Petti C, Ribero D, Russolillo N, Muratore A, et al. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 2011; 1: 508-23. doi: 10.1158/2159-8290.CD-11-0109.
106. Ciardiello F, and Normanno N. HER2 signaling and resistance to the anti-EGFR monoclonal antibody cetuximab: a further step toward personalized medicine for patients with colorectal cancer. Cancer Discov. 2011; 1: 472-4. doi: 10.1158/2159-8290.CD-11-0261.
107. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, and Halmos B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005; 352: 786-92. doi: 10.1056/NEJMoa044238.
108. Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, Kris MG, Miller VA, Ladanyi M, and Riely GJ. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013; 19: 2240-7. doi: 10.1158/1078-0432.CCR-12-2246.
109. Montagut C, Dalmases A, Bellosillo B, Crespo M, Pairet S, Iglesias M, Salido M, Gallen M, Marsters S, Tsai SP, Minoche A, Seshagiri S, Serrano S, et al. Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nat Med. 2012; 18: 221-3. doi: 10.1038/nm.2609.
110. Esposito C, Rachiglio AM, La Porta ML, Sacco A, Roma C, Iannaccone A, Tatangelo F, Forgione L, Pasquale R, Barbaro A, Botti G, Ciardiello F, and Normanno N. The S492R EGFR ectodomain mutation is never detected in KRAS wild-type colorectal carcinoma before exposure to EGFR monoclonal antibodies. Cancer Biol Ther. 2013; 14: 1143-6. doi: 10.4161/cbt.26340.
111. Ellis LM, and Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer. 2008; 8: 579-91. doi: 10.1038/nrc2403.
112. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, MacDonald DD, Jin DK, Shido K, Kerns SA, Zhu Z, Hicklin D, Wu Y, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the premetastatic niche. Nature. 2005; 438: 820-7. doi: 10.1038/nature04186.
113. Ciardiello F, Bianco R, Caputo R, Caputo R, Damiano V, Troiani T, Melisi D, De Vita F, De Placido S, Bianco AR, and Tortora G. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin Cancer Res. 2004; 10: 784-93. doi: 10.1158/1078-0432.CCR-1100-03.
114. Bianco R, Rosa R, Damiano V, Daniele G, Gelardi T, Garofalo S, Tarallo V, De Falco S, Melisi D, Benelli R, Albini A, Ryan A, Ciardiello F, et al. Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells. Clin Cancer Res. 2008; 14: 5069-80. doi: 10.1158/1078-0432.CCR-07-4905.
115. Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, Erdkamp FL, Vos AH, van Groeningen CJ, Sinnige HA, Richel DJ, Voest EE, Dijkstra JR, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med. 2009; 360: 563-72. doi: 10.1056/NEJMoa0808268.
116. Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, Marshall J, Cohn A, McCollum D, Stella P, Deeter R, Shahin S, and Amado RG. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol. 2009; 27: 672-80 doi: 10.1200/JCO.2008.19.8135.
117. Derangere V, Fumet JD, Boidot R, Bengrine L, Limagne E, Chevriaux A, Vincent J, Ladoire S, Apetoh L, Rebe C, and Ghiringhelli F. Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer? Oncotarget. 2016; 7: 9309-21. doi: 10.18632/oncotarget.7008.
118. Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, and Bardelli A. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 2008; 26: 5705-12. doi: 10.1200/JCO.2008.18.0786.
119. Zhang YJ, Tian XQ, Sun DF, Zhao SL, Xiong H, and Fang JY. Combined inhibition of MEK and mTOR signaling inhibits initiation and progression of colorectal cancer. Cancer Invest. 2009; 27: 273-85. doi: 10.1080/07357900802314893.
120. Markman B, Atzori F, Perez-Garcia J, Tabernero J, and Baselga J. Status of PI3K inhibition and biomarker development in cancer therapeutics. Ann Oncol. 2010; 21: 683-91. doi: 10.1093/annonc/mdp347.
121. Richman SD, Southward K, Chambers P, Cross D, Barrett J, Hemmings G, Taylor M, Wood H, Hutchins G, Foster JM, Oumie A, Spink KG, Brown SR, et al. HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials. J Pathol. 2016; 238: 562-70. doi: 10.1002/path.4679.
122. Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, Ye Q, Lobo JM, She Y, Osman I, Golub TR, Sebolt-Leopold J, Sellers WR, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature. 2006; 439: 358-62. doi: 10.1038/nature04304.
123. Queralt B, Cuyas E, Bosch-Barrera J, Massaguer A, de Llorens R, Martin-Castillo B, Brunet J, Salazar R, and Menendez JA. Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer. Oncotarget. 2016. doi: 10.18632/oncotarget.11985.